A technical guide to marker genes in genetically modified crops — selectable and reporter genes, antibiotic resistance marker safety assessment, PCR detection methods, and U.S. bioengineered food disclosure requirements.

Executive Summary

A marker gene is a gene deliberately included alongside a target trait during the genetic transformation of a plant or microorganism, used to identify which cells successfully took up the intended genetic modification. Historically, the most common marker genes conferred resistance to a specific antibiotic or herbicide, which raised public and regulatory concern about the fate of these genes once ingested. This guide covers the biology of selectable and reporter marker genes, the safety assessment history led by EFSA, WHO, and Codex, the PCR-based methods labs use to detect them (both for authorized-GMO confirmation and for screening unauthorized genetically modified microorganisms), and how marker gene detectability intersects with the U.S. National Bioengineered Food Disclosure Standard.

Introduction

For food scientists and regulatory teams, “marker gene” most often surfaces in three practical contexts: understanding how a GM crop or ingredient was developed, assessing whether a specific marker gene raises a distinct safety question beyond the primary introduced trait, and determining whether a marker gene (or any other bioengineered genetic material) is analytically detectable in a finished food — which is the trigger point for U.S. disclosure obligations.

Scientific Background: What Marker Genes Are and Why They’re Used

Genetic transformation of plant cells is inherently inefficient — only a small fraction of treated cells actually take up the intended DNA construct. Because there is no way to visually distinguish a successfully transformed cell from an untransformed one, developers include a second gene, the marker gene, alongside the gene of interest specifically to make successful transformation identifiable.

There are two principal categories:

Selectable marker genes confer resistance to a selective agent — most commonly an antibiotic (e.g., kanamycin, via the nptII gene, or hygromycin, via aphIV/hph) or a herbicide (e.g., glyphosate or glufosinate tolerance genes). Cells are exposed to the selective agent during development; only cells that took up the marker gene (and, by extension, the linked gene of interest) survive, allowing researchers to efficiently identify successfully transformed material.
Reporter genes produce a product that can be detected visually or through a simple biochemical assay (for example, genes producing a colored or fluorescent product), rather than conferring resistance to a selective agent.

Because the marker gene has no function once the transformed plant has been selected and developed, it typically remains in the final commercial crop as a non-functional passenger sequence unless specifically removed.

Technical Discussion: Safety Assessment of Antibiotic Resistance Marker Genes

The use of antibiotic resistance marker genes (ARMGs) in GM crops attracted particular regulatory scrutiny because of a theoretical concern: that the resistance gene could transfer from the plant’s DNA to bacteria in the human or animal gastrointestinal tract, potentially compromising the clinical effectiveness of the corresponding antibiotic — a process known as horizontal gene transfer (HGT).

This question has been examined extensively by international and regional food safety bodies:

The European Food Safety Authority (EFSA), in a joint opinion of its GMO and BIOHAZ panels, concluded that transfer of ARMGs from GM plants to bacteria has not been demonstrated to occur either under natural conditions or in laboratory studies, and identified the lack of DNA sequence similarity between plant and bacterial genomes as a key barrier to any such transfer.
Regulatory risk assessments have noted that feeding studies using GM grains or purified plasmid DNA have not detected horizontal transfer of GM DNA to gastrointestinal bacteria in animals.
The World Health Organization and the Codex Alimentarius Commission have both noted that the theoretical potential for ARMG transfer from plants to gut microorganisms is considered very low, particularly since resistance genes to antibiotics such as kanamycin, neomycin, and streptomycin already occur widely across natural bacterial environments independent of any GM crop exposure.
Where a specific ARMG or its gene product is found through safety evaluation to present a risk to human health — for example, where the corresponding antibiotic is clinically important — regulatory guidance directs that the marker gene or its product should not be present in the food, which has led to increased use of alternative marker systems and marker-excision technologies (discussed below) in newer GM crop development.

It’s worth noting this remains an area where scientific consensus (as reflected in EFSA, WHO, and Codex assessments) differs from the position taken by some advocacy organizations, which continue to argue that ARMG-containing crops should be removed from the market as a precaution given the broader public health concern around antibiotic resistance; food safety professionals should be aware both of the weight of current regulatory scientific opinion and of this ongoing public debate when communicating about ARMGs.

Alternative and Marker-Free Systems

In response to both the ARMG safety debate and broader consumer perception concerns, several alternative approaches have been developed and adopted in newer GM crop development:

Alternative, non-antibiotic marker genes, such as herbicide-tolerance markers or genes like ptxD (conferring the ability to use phosphite as a phosphorus source), which avoid antibiotic resistance entirely.
Marker excision/removal systems (e.g., Cre-lox recombination systems), which allow the marker gene to be removed from the plant genome after successful selection, leaving only the intended trait gene in the final commercial line.

Detection Methods: How Marker Genes Are Identified in Food and Ingredients

PCR (polymerase chain reaction)-based methods are the standard analytical approach for detecting marker genes and other GM-associated genetic elements in food, feed, and ingredient testing:

Real-time (quantitative) PCR is typically used as a first-line screening method, targeting conserved marker gene sequences (e.g., nptII, aphIV) or common regulatory elements (promoters, terminators) associated with GM constructs.
Conventional PCR followed by Sanger sequencing is used as a confirmatory step where a screening result is positive or ambiguous, to determine the full-length sequence of the detected gene and support a more definitive risk evaluation.
Melting curve analysis is often used alongside quantitative PCR to verify assay specificity and rule out false positives from non-target sequences.

An important, more recent application of this same methodology is the screening of unauthorized genetically modified microorganisms (GMMs) — for example, in fermentation-derived food and feed enzymes, additives, or flavorings — for antimicrobial resistance (AMR) marker genes that were never authorized for use in the commercialized product. This has emerged as a food and feed safety enforcement concern in the EU in particular, where unauthorized GMM contamination in fermentation products falls under GMO commercialization regulation, and PCR-based AMR gene screening (including for genes such as those conferring tetracycline resistance) has been developed specifically to support enforcement laboratories in detecting this issue.

Regulatory Requirements: Marker Genes and U.S. Bioengineered Food Disclosure

In the United States, marker gene detectability connects directly to a specific compliance question under the USDA National Bioengineered Food Disclosure Standard (7 CFR Part 66), which requires disclosure of foods that are or may be bioengineered (BE).

Key points relevant to marker genes and detection:

The Standard defines a bioengineered substance as one containing genetic material modified through in vitro recombinant DNA techniques, where the modification could not otherwise be obtained through conventional breeding or found in nature.
Disclosure is required when a food is made from an ingredient on USDA’s List of Bioengineered Foods and the modified genetic material — which can include marker gene sequences along with the primary trait gene — is detectable in the finished food.
Critically, the Standard includes a detectability exemption: highly refined ingredients (such as refined soybean or corn oil derived from bioengineered crops) may not require disclosure if the refining process has been validated to render modified genetic material, including any marker gene sequence, undetectable in the final product.
Once a refining process has been validated under 7 CFR 66.9(b) to render modified genetic material undetectable, additional testing is not required for subsequent production runs through that same validated process, provided no significant process changes occur and validation records are maintained.
Analytical testing used to support a detectability determination must meet specified performance standards under 7 CFR 66.9(c), covering laboratory quality assurance, method validation and verification, demonstrated testing accuracy, and sufficient assay sensitivity for the intended purpose.

For ingredient sourcing and regulatory teams, this means marker gene detectability testing is not merely an academic biotechnology question — it is the specific analytical basis on which a highly refined ingredient may be exempted from BE disclosure, and documentation of that validated non-detectability needs to be maintained as a compliance record.

Best Practices for Food Manufacturers and Regulatory Teams

Obtain supplier documentation confirming whether an ingredient derived from a bioengineered crop has been processed through a validated refining process rendering genetic material (including any marker gene) non-detectable, rather than assuming refined ingredients are automatically exempt.
When sourcing fermentation-derived enzymes, additives, or flavorings, confirm with suppliers that any production microorganism has undergone appropriate authorization and does not carry undisclosed antimicrobial resistance marker genes.
Maintain validation and testing records supporting any BE disclosure determination in a format that meets the analytical performance standards specified in the Standard’s implementing regulations.
Track ongoing developments in marker-free and alternative marker gene technologies when evaluating new GM/BE ingredient sources, since newer transformation systems increasingly avoid antibiotic resistance markers specifically to reduce this category of regulatory and consumer scrutiny.
When communicating with consumers or the public about GM crop safety, distinguish clearly between the weight of current regulatory scientific assessment (EFSA, WHO, Codex) and the separate, ongoing advocacy debate about antibiotic resistance marker genes, rather than presenting either side as the sole settled position.

Frequently Asked Questions

What is the difference between a selectable marker gene and the target gene of interest in a GM crop? The marker gene is included specifically to help identify successfully transformed cells during development (e.g., by conferring antibiotic or herbicide resistance); the gene of interest is the trait actually intended for the final commercial crop (e.g., pest resistance or herbicide tolerance in the crop itself). The marker gene typically serves no further purpose once selection is complete.

Are antibiotic resistance marker genes in GM crops considered unsafe? Current assessments from EFSA, WHO, and Codex have concluded that the risk of antibiotic resistance marker genes transferring from GM plants to gut bacteria is very low and has not been demonstrated in available studies, though case-by-case safety evaluation is still required, and some antibiotic resistance genes considered clinically important may be restricted from use even where general transfer risk is assessed as low.

How do labs test for marker genes in food or ingredients? The standard approach is PCR-based: real-time quantitative PCR for initial screening against known marker gene or GM-construct sequences, followed by conventional PCR and sequencing to confirm a positive result where needed.

Does a refined oil from a bioengineered crop always require a bioengineered food disclosure? Not necessarily — if the refining process has been validated to render modified genetic material (including marker gene sequences) undetectable in the final product, and appropriate records are maintained, disclosure may not be required under the U.S. National Bioengineered Food Disclosure Standard.

Are newer GM crops still using antibiotic resistance marker genes? Increasingly, no — many newer transformation systems use alternative, non-antibiotic marker genes or marker-excision technologies (such as Cre-lox systems) that remove the marker gene after successful selection, partly in response to the safety and consumer-perception concerns associated with ARMGs.

Key Takeaways

Marker genes are auxiliary genes used to identify successfully transformed cells during GM crop development, distinct from the primary trait gene intended for commercialization.
Antibiotic resistance marker genes have undergone extensive safety review by EFSA, WHO, and Codex, which have generally concluded the risk of gene transfer to gut bacteria is very low, though this remains an area of continued public debate.
PCR-based methods (real-time PCR screening, confirmatory conventional PCR/sequencing) are the standard laboratory approach for marker gene detection, including for screening unauthorized GM microorganisms in fermentation-derived ingredients.
Under the U.S. National Bioengineered Food Disclosure Standard, marker gene and other modified genetic material detectability is the specific technical basis for the refined-ingredient disclosure exemption — making detection testing a compliance-relevant activity, not only a research one.
Newer GM crop development increasingly favors alternative marker systems or marker-excision technology over legacy antibiotic resistance markers.

Conclusion

Marker genes illustrate how a purely developmental tool in plant biotechnology became a specific regulatory and analytical focus point in food safety — first as a subject of dedicated risk assessment by international bodies, and now as the precise technical basis for a labeling exemption under U.S. bioengineered food disclosure rules. For QA, regulatory, and sourcing teams, understanding marker gene biology is less about biotechnology curiosity and more about being able to correctly interpret supplier documentation, evaluate refining-process validation claims, and communicate accurately about GM crop safety questions that combine well-established regulatory science with genuinely ongoing public debate.

References

EFSA. EFSA evaluates antibiotic resistance marker genes in GM plants (joint GMO/BIOHAZ Panel opinion).
Office of the Gene Technology Regulator (Australia). Risk Assessment Reference: Marker Genes in GM Plants (2024).
Centre for Food Safety, Hong Kong. Genetically Modified Food – Antibiotic Resistance Marker Gene.
Springer Nature / Bulletin of the National Research Centre. Exploratory and confirmatory molecular approaches to determine genetically modified status in different crops.
Springer Nature / Food Analytical Methods. Strategy to Detect Genetically Modified Bacteria Carrying Tetracycline Resistance Gene in Fermentation Products.
U.S. USDA Agricultural Marketing Service. National Bioengineered Food Disclosure Standard, 7 CFR Part 66.
Congressional Research Service. The National Bioengineered Food Disclosure Standard: Overview and Selected Considerations (R46183).